Skip to main content
SpringerLink
Log in

Neurobiology and Evidence-Based Review on Novel Therapeutic Strategy for Treatment-Resistant Depression (TRD)

  • Chapter
  • First Online:
Understanding Depression

Abstract

Treatment refractory depression (TRD) causes more burden although newer antidepressants have been introduced in last decades. In this chapter, the authors will discuss the novel treatment approaches based upon new neurobiological models and review the evidence-based treatments. Special consideration will be given to the inflammation hypothesis, ketamine, ECT, and deep brain stimulation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Anderson IM, Blamire A, Branton T, Brigadoi S, Clark R, Downey D, et al. Efficacy and mechanism evaluation randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (ketamine-ECT study). Southampton: NIHR Journals Library; 2017.

    Google Scholar 

  • Bauer M, Ströhle A. Behandlungsstrategien bei prophylaxeresistenten bipolaren Störungen. Nervenarzt. 1999;70(7):587–99.

    Article  CAS  PubMed  Google Scholar 

  • Berlim MT, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol. 2007;17(11):696–707.

    Article  CAS  PubMed  Google Scholar 

  • Best MW, Fitzpatrick M, Milev R, Bowie CR, Jokic R. Utility of the berlin questionnaire for predicting obstructive sleep apnea in individuals with treatment-resistant depression. Sleep Breath. 2013;17(4):1221–7.

    Article  PubMed  Google Scholar 

  • Birmaher B, Axelson D, Goldstein B, Strober M, Gill MK, Hunt J, et al. Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: the Course and Outcome of Bipolar Youth (COBY) Study. Focus. 2012;10(3):389–400.

    Article  Google Scholar 

  • Bryson EO, Kellner CH. Ketamine anesthesia for electroconvulsive therapy. Psychiatr Times. 2014;31(5):38.

    Google Scholar 

  • Caddy C, Amit BH, McCloud TL, Rendell JM, Furukawa TA, McShane R, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. 2015;9.

    Google Scholar 

  • Conca A, König P, Hausmann A. Transcranial magnetic stimulation induces ‘pseudoabsence seizure’. Acta Psychiatr Scand. 2000;101(3):246–9.

    Article  CAS  PubMed  Google Scholar 

  • Coppen A, Abou-Saleh M, Milln P, Metcalfe M, Harwood J, Bailey J. Dexamethasone suppression test in depression and other psychiatric illness. Br J Psychiatry. 1983;142(5):498.

    Article  CAS  PubMed  Google Scholar 

  • Cretaz E, Brunoni AR, Lafer B. Magnetic seizure therapy for unipolar and bipolar depression: a systematic review. Neural Plast. 2015;2015:1–9.

    Article  Google Scholar 

  • Cusin C, Iovieno N, Iosifescu DV, Nierenberg AA, Fava M, Rush AJ, et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry. 2013;74(7):e636–41.

    Article  CAS  PubMed  Google Scholar 

  • Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry. 2000;61(Suppl 6):7–11.

    CAS  PubMed  Google Scholar 

  • DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015;1345:47–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dougherty DD, Rezai AR, Carpenter LL, Howland RH, Bhati MT, O’Reardon JP, et al. A randomized sham-controlled trial of deep brain stimulation of the ventral capsule/ventral striatum for chronic treatment-resistant depression. Biol Psychiatry. 2015;78(4):240–8.

    Article  PubMed  Google Scholar 

  • Fenoy AJ, Schulz P, Selvaraj S, Burrows C, Spiker D, Cao B, et al. Deep brain stimulation of the medial forebrain bundle: distinctive responses in resistant depression. J Affect Disord. 2016;203:143–51.

    Article  PubMed  Google Scholar 

  • Goodwin G, Haddad P, Ferrier I, Aronson J, Barnes T, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495–553.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gorwood P, Rouillon F, Even C, Falissard B, Corruble E, Moran P. Treatment response in major depression: effects of personality dysfunction and prior depression. Br J Psychiatry. 2010;196(2):139–42.

    Article  CAS  PubMed  Google Scholar 

  • Gould TD, Zanos P, Zarate CA Jr. Ketamine mechanism of action: separating the wheat from the chaff. Neuropsychopharmacology. 2017;42(1):368–9.

    Article  PubMed  Google Scholar 

  • Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller H-J, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81–109.

    Article  PubMed  Google Scholar 

  • Hassan AK, Farmer KC, Brahm NC, Neas BR. Evaluating antidepressant treatment prior to adding second-line therapies among patients with treatment-resistant depression. Int J Clin Pharm. 2016;38(2):429–37.

    Article  CAS  PubMed  Google Scholar 

  • Hirschfeld R, Bowden CL, Gitlin MJ, Keck PE, Suppes T, Thase ME, et al. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 2002;159(44 Suppl):1–50.

    Google Scholar 

  • Hirschfeld RM. Guidelines for the long-term treatment of depression. J Clin Psychiatry. 1994;55:61–9. discussion 70-61

    PubMed  Google Scholar 

  • Hirschfeld RM. Guideline watch: practice guideline for the treatment of patients with bipolar disorder. Arlington: American Psychiatric Association; 2005.

    Google Scholar 

  • Iosifescu DV, Bankier B, Fava M. Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. Curr Psychiatry Rep. 2004;6(3):193–201.

    Article  PubMed  Google Scholar 

  • Bauer IE, Soares JC, Selek S, Meyer TD. Volume editors: a volume in the series. The link between refractoriness and neuroprogression in treatment-resistant bipolar disorder. In: Halaris BLGA (Chicago), editors. Modern trends in pharmacopsychiatry (vol. neuroprogression in psychiatric disorders). Basel: Karger Publishers; 2016.

    Google Scholar 

  • Jarventausta K, Sorri A, Kampman O, Bjorkqvist M, Tuohimaa K, Hamalainen M, et al. Changes in interleukin-6 levels during electroconvulsive therapy may reflect the therapeutic response in major depression. Acta Psychiatr Scand. 2017;135(1):87–92.

    Article  CAS  PubMed  Google Scholar 

  • Keitner GI, Mansfield AK. Management of treatment-resistant depression. Psychiatr Clin North Am. 2012;35(1):249–65.

    Article  PubMed  Google Scholar 

  • Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):18.

    CAS  PubMed  Google Scholar 

  • Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007;39(1):13.

    Article  PubMed  Google Scholar 

  • Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS One. 2013;8(10):e76882.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lally N, Nugent AC, Luckenbaugh DA, Niciu MJ, Roiser JP, Zarate CA. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol. 2015;29(5):596–607.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lepine BA, Moreno RA, Campos RN, Couttolenc BF. Treatment-resistant depression increases health costs and resource utilization. Rev Bras Psiquiatr. 2012;34(4):379–88.

    Article  PubMed  Google Scholar 

  • Liu CS, Carvalho AF, McIntyre RS. Towards a “metabolic” subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction. CNS Neurol Disord Drug Targets. 2014;13(10):1693–707.

    Article  PubMed  Google Scholar 

  • Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther. 2009;123(2):143–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Maher DP, Chen L, Mao J. Intravenous ketamine infusions for neuropathic pain management: a promising therapy in need of optimization. Anesth Analg. 2017;124(2):661–74.

    Article  CAS  PubMed  Google Scholar 

  • Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45(5):651–60.

    Article  CAS  PubMed  Google Scholar 

  • Micallef-Trigona B. Comparing the effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in the treatment of depression: a systematic review and meta-analysis. Depress Res Treat. 2014;2014:135049.

    PubMed  PubMed Central  Google Scholar 

  • Milev RV, Giacobbe P, Kennedy SH, Blumberger DM, Daskalakis ZJ, Downar J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. Neurostimulation treatments. Can J Psychiatr. 2016;61(9):561–75.

    Article  Google Scholar 

  • Nierenberg AA, Petersen TJ, Alpert JE. Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy. J Clin Psychiatry. 2003;64(Suppl 15):13–7.

    PubMed  Google Scholar 

  • Pacchiarotti I, Mazzarini L, Colom F, Sanchez-Moreno J, Girardi P, Kotzalidis GD, et al. Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand. 2009;120(6):429–40.

    Article  CAS  PubMed  Google Scholar 

  • Passione R. Italian psychiatry in an international context: Ugo Cerletti and the case of electroshock. Hist Psychiatry. 2004;15(1):83–104.

    Article  PubMed  Google Scholar 

  • Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry. 2005;66(Suppl 8):22–9.

    CAS  PubMed  Google Scholar 

  • Post T, Kemmler G, Krassnig T, Brugger A, Hausmann A. Efficacy of continuation and maintenance electroconvulsive therapy (c/m ECT) in the treatment of patients with therapy-resistant affective disorders: a retrospective analysis. Neuropsychiatrie. 2015;29(3):133.

    Article  PubMed  Google Scholar 

  • Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5):522–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor-alpha antagonist infliximab in treatment resistant depression: role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ryan KM, Glaviano A, O’Donovan SM, Kolshus E. Electroconvulsive therapy modulates plasma pigment epithelium-derived factor in depression: a proteomics study. Transl Psychiatry. 2017;7(3):e1073.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):10–7.

    CAS  PubMed  Google Scholar 

  • Sanacora G, Heimer H, Hartman D, Mathew SJ, Frye M, Nemeroff C, et al. Balancing the promise and risks of ketamine treatment for mood disorders. Neuropsychopharmacology. 2017;42(6):1179–81.

    Article  CAS  PubMed  Google Scholar 

  • Sasaki T, Hashimoto K, Oda Y, Ishima T, Yakita M, Kurata T, et al. Increased serum levels of oxytocin in “Treatment Resistant Depression in Adolescents (TRDIA)” Group. PLoS One. 2016;11(8):e0160767.

    Article  PubMed  PubMed Central  Google Scholar 

  • Schatzberg AF. A word to the wise about ketamine. Am J Psychiatry. 2014;171(3):262–4.

    Article  PubMed  Google Scholar 

  • Schoeyen HK, Kessler U, Andreassen OA, Auestad BH, Bergsholm P, Malt UF, et al. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am J Psychiatry. 2015;172(1):41–51.

    Article  PubMed  Google Scholar 

  • Selek S, Passos IC, Soares JC. The management of treatment resistance bipolar disorder. In: Carvalho AF, Vieta E, editors. The treatment of bipolar disorder. 1st ed. Oxford: Oxford University Press; 2017. p. 338–56.

    Google Scholar 

  • Shamseddeen W, Asarnow JR, Clarke G, Vitiello B, Wagner KD, Birmaher B, et al. Impact of physical and sexual abuse on treatment response in the Treatment of Resistant Depression in Adolescent Study (TORDIA). J Am Acad Child Adolesc Psychiatry. 2011;50(3):293–301.

    Article  PubMed  PubMed Central  Google Scholar 

  • Shiroma PR, Albott CS, Johns B, Thuras P, Wels J, Lim KO. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17(11):1805–13.

    Article  CAS  PubMed  Google Scholar 

  • Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816–26.

    Article  PubMed  Google Scholar 

  • Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–70.

    Article  PubMed  Google Scholar 

  • Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 2011;31(4):512–6.

    Article  CAS  PubMed  Google Scholar 

  • The UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361(9360):799–808.

    Article  Google Scholar 

  • Torres-Sanchez S, Perez-Caballero L, Berrocoso E. Cellular and molecular mechanisms triggered by deep brain stimulation in depression: a preclinical and clinical approach. Prog Neuropsychopharmacol Biol Psychiatry. 2017;73:1–10.

    Article  CAS  PubMed  Google Scholar 

  • Vaidya NA, Mahableshwarkar AR, Shahid R. Continuation and maintenance ECT in treatment-resistant bipolar disorder. J ECT. 2003;19(1):10–6.

    Article  PubMed  Google Scholar 

  • Voineskos D, Levinson AJ, Sun Y, Barr MS, Farzan F, Rajji TK, et al. The relationship between cortical inhibition and electroconvulsive therapy in the treatment of major depressive disorder. Sci Rep. 2016;6:37461.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • WHO Expert Committee on Drug Dependence. WHO Expert Committee on Drug Dependence: thirty-sixth report, vol. 991. Geneva: World Health Organization; 2015.

    Google Scholar 

  • Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA

    Salih Selek & Jair C. Soares

Authors
  1. Salih Selek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jair C. Soares
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Salih Selek .

Editor information

Editors and Affiliations

  1. College of Medicine, Korea University, Kyonggi-do, Korea (Republic of)

    Yong-Ku Kim

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Selek, S., Soares, J.C. (2018). Neurobiology and Evidence-Based Review on Novel Therapeutic Strategy for Treatment-Resistant Depression (TRD). In: Kim, YK. (eds) Understanding Depression. Springer, Singapore. https://doi.org/10.1007/978-981-10-6577-4_19

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-6577-4_19

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-6576-7

  • Online ISBN: 978-981-10-6577-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation